Skip to content
OpenCapital
Get started

CytomX Therapeutics CTMX Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

SPS Commerce logo
SPS CommerceSPSC
$4.87M+54.2%
AvePoint, Inc. logo
AvePoint, Inc.AVPT
$4.39M+4.3%
Q2 Holdings logo
Q2 HoldingsQTWO
$45.49M+26.0%
AMN Healthcare logo
AMN HealthcareAMN
-$4.41M-312%
Rackspace Technology, Inc. logo
Rackspace Technology, Inc.RXT
$35.6M+483%
Calix logo
CalixCALX
$675K-80.6%

Other financials

Income statement

See full
Revenue$10.3M-79.9%
Operating income-$19.7M-187%
Net income-$18.2M-178%
EPS (diluted)-$0.10-137%

Balance sheet

See full
Cash & equivalents$28.8M-39.4%
Total debt$2.9M-65.0%
Total equity$319.9M+1,177%
Total assets$359.4M+265%

Cash flow

See full
Operating cash flow-$25.5M-21.4%
CapEx--100%
Free cash flow-$25.5M-20.7%

Valuation

See full
Market cap$711.89M+94.8%
Enterprise value$685.92M+110%
P/S20×+17.6×

Profitability

See full
Operating margin-181.9%-206pp
Net margin-166.4%-195pp
FCF margin-225.6%-334pp

Returns & leverage

See full
Return on equity-34.3%—
Debt / equity0×-0.3×
Current ratio10.4×+8.7×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's increase (decrease) in contract liabilities and current deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CytomX Therapeutics's increase (decrease) in contract liabilities and current deferred income?
CytomX Therapeutics (CTMX) reported increase (decrease) in contract liabilities and current deferred income of -$9.61M in Q1 2026.
How has CytomX Therapeutics's increase (decrease) in contract liabilities and current deferred income changed year-over-year?
CytomX Therapeutics's increase (decrease) in contract liabilities and current deferred income increased by 78.5% year-over-year, from -$44.62M to -$9.61M.
What is the long-term trend for CytomX Therapeutics's increase (decrease) in contract liabilities and current deferred income?
Over 4 years (2021 to 2025), CytomX Therapeutics's increase (decrease) in contract liabilities and current deferred income has grown at a 18.1% compound annual growth rate (CAGR), from -$33.95M to -$66.15M.